# The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

> **NCT04312282** · PHASE1 · TERMINATED · sponsor: **Odonate Therapeutics, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Tesetaxel
- **DRUG:** Tesetaxel
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT04312282
- **Lead sponsor:** Odonate Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-06
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-06-15
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** The Sponsor has discontinued the development of tesetaxel
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04312282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04312282, "The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04312282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*